BACKGROUND: Patients with amnestic mild cognitive impairment (MCI) represent an important clinical group as they are at increased risk of developing Alzheimer disease (AD). (11)C-PIB PET is an in vivo marker of brain amyloid load. OBJECTIVE: To assess the rates of conversion of MCI to AD during a 3-year follow-up period and to compare levels of amyloid deposition between MCI converters and nonconverters. METHODS: Thirty-one subjects with MCI with baseline (11)C-PIB PET, MRI, and neuropsychometry have been clinically followed up for 1 to 3 years (2.68 +/- 0.6 years). Raised cortical (11)C-PIB binding in subjects with MCI was detected with region of interest analysis and statistical parametric mapping. RESULTS: Seventeen of 31 (55%) subjects with MCI had increased (11)C-PIB retention at baseline and 14 of these 17 (82%) clinically converted to AD during follow-up. Only one of the 14 PIB-negative MCI cases converted to AD. Of the PIB-positive subjects with MCI, half (47%) converted to AD within 1 year of baseline PIB PET, these faster converters having higher tracer-retention values than slower converters in the anterior cingulate (p = 0.027) and frontal cortex (p = 0.031). Seven of 17 (41%) subjects with MCI with known APOE status were epsilon4 allele carriers, this genotype being associated with faster conversion rates in PIB-positive subjects with MCI (p = 0.035). CONCLUSIONS: PIB-positive subjects with mild cognitive impairment (MCI) are significantly more likely to convert to AD than PIB-negative patients, faster converters having higher PIB retention levels at baseline than slower converters. In vivo detection of amyloid deposition in MCI with PIB PET provides useful prognostic information.
BACKGROUND:Patients with amnestic mild cognitive impairment (MCI) represent an important clinical group as they are at increased risk of developing Alzheimer disease (AD). (11)C-PIB PET is an in vivo marker of brain amyloid load. OBJECTIVE: To assess the rates of conversion of MCI to AD during a 3-year follow-up period and to compare levels of amyloid deposition between MCI converters and nonconverters. METHODS: Thirty-one subjects with MCI with baseline (11)C-PIB PET, MRI, and neuropsychometry have been clinically followed up for 1 to 3 years (2.68 +/- 0.6 years). Raised cortical (11)C-PIB binding in subjects with MCI was detected with region of interest analysis and statistical parametric mapping. RESULTS: Seventeen of 31 (55%) subjects with MCI had increased (11)C-PIB retention at baseline and 14 of these 17 (82%) clinically converted to AD during follow-up. Only one of the 14 PIB-negative MCI cases converted to AD. Of the PIB-positive subjects with MCI, half (47%) converted to AD within 1 year of baseline PIB PET, these faster converters having higher tracer-retention values than slower converters in the anterior cingulate (p = 0.027) and frontal cortex (p = 0.031). Seven of 17 (41%) subjects with MCI with known APOE status were epsilon4 allele carriers, this genotype being associated with faster conversion rates in PIB-positive subjects with MCI (p = 0.035). CONCLUSIONS: PIB-positive subjects with mild cognitive impairment (MCI) are significantly more likely to convert to AD than PIB-negative patients, faster converters having higher PIB retention levels at baseline than slower converters. In vivo detection of amyloid deposition in MCI with PIB PET provides useful prognostic information.
Authors: Timo Grimmer; Gjermund Henriksen; Hans-Jürgen Wester; Hans Förstl; William E Klunk; Chester A Mathis; Alexander Kurz; Alexander Drzezga Journal: Neurobiol Aging Date: 2008-03-17 Impact factor: 4.673
Authors: S Larrieu; L Letenneur; J M Orgogozo; C Fabrigoule; H Amieva; N Le Carret; P Barberger-Gateau; J F Dartigues Journal: Neurology Date: 2002-11-26 Impact factor: 9.910
Authors: William E Klunk; Henry Engler; Agneta Nordberg; Yanming Wang; Gunnar Blomqvist; Daniel P Holt; Mats Bergström; Irina Savitcheva; Guo-feng Huang; Sergio Estrada; Birgitta Ausén; Manik L Debnath; Julien Barletta; Julie C Price; Johan Sandell; Brian J Lopresti; Anders Wall; Pernilla Koivisto; Gunnar Antoni; Chester A Mathis; Bengt Långström Journal: Ann Neurol Date: 2004-03 Impact factor: 10.422
Authors: Alexander Hammers; Richard Allom; Matthias J Koepp; Samantha L Free; Ralph Myers; Louis Lemieux; Tejal N Mitchell; David J Brooks; John S Duncan Journal: Hum Brain Mapp Date: 2003-08 Impact factor: 5.038
Authors: Laurel A Beckett; Danielle J Harvey; Anthony Gamst; Michael Donohue; John Kornak; Hao Zhang; Julie H Kuo Journal: Alzheimers Dement Date: 2010-05 Impact factor: 21.566
Authors: Erin R Foster; Meghan C Campbell; Michelle A Burack; Johanna Hartlein; Hubert P Flores; Nigel J Cairns; Tamara Hershey; Joel S Perlmutter Journal: Mov Disord Date: 2010-11-15 Impact factor: 10.338
Authors: Liana G Apostolova; Kristy S Hwang; John P Andrawis; Amity E Green; Sona Babakchanian; Jonathan H Morra; Jeffrey L Cummings; Arthur W Toga; John Q Trojanowski; Leslie M Shaw; Clifford R Jack; Ronald C Petersen; Paul S Aisen; William J Jagust; Robert A Koeppe; Chester A Mathis; Michael W Weiner; Paul M Thompson Journal: Neurobiol Aging Date: 2010-06-11 Impact factor: 4.673
Authors: D P Devanand; Arthur Mikhno; Gregory H Pelton; Katrina Cuasay; Gnanavalli Pradhaban; J S Dileep Kumar; Neil Upton; Robert Lai; Roger N Gunn; V Libri; Xinhua Liu; Ronald van Heertum; J John Mann; Ramin V Parsey Journal: J Geriatr Psychiatry Neurol Date: 2010-04-29 Impact factor: 2.680
Authors: Lisa Mosconi; Juha O Rinne; Wai H Tsui; Valentina Berti; Yi Li; Huiyu Wang; John Murray; Noora Scheinin; Kjell Någren; Schantel Williams; Lidia Glodzik; Susan De Santi; Shankar Vallabhajosula; Mony J de Leon Journal: Proc Natl Acad Sci U S A Date: 2010-03-15 Impact factor: 11.205
Authors: Lisa Mosconi; John Murray; Wai H Tsui; Yi Li; Nicole Spector; Alexander Goldowsky; Schantel Williams; Ricardo Osorio; Pauline McHugh; Lidia Glodzik; Shankar Vallabhajosula; Mony J de Leon Journal: Neurology Date: 2014-02-12 Impact factor: 9.910